Story perspectives

J&J Launches Four Drugs on TrumpRx, Pledges $55B Investment

4/25/2026

Summary

Story summary

Johnson & Johnson will begin selling four drugs—Invokamet, Invokamet XR, Invokana, and Xarelto—on the TrumpRx website on Friday, April 24, 2026, doubling the platform’s drug count.
The rollout follows a voluntary January agreement in which Johnson & Johnson agreed to lower Medicaid prices and receive a tariff exemption.
Johnson & Johnson has pledged a $55 billion investment in Pennsylvania and North Carolina, targeting cash-pay patients whose insurance does not cover prescriptions through TrumpRx.

1 of 1

Story summary

Johnson & Johnson will begin selling four drugs—Invokamet, Invokamet XR, Invokana, and Xarelto—on the TrumpRx website on Friday, April 24, 2026, doubling the platform’s drug count.
The rollout follows a voluntary January agreement in which Johnson & Johnson agreed to lower Medicaid prices and receive a tariff exemption.
Johnson & Johnson has pledged a $55 billion investment in Pennsylvania and North Carolina, targeting cash-pay patients whose insurance does not cover prescriptions through TrumpRx.